Clinical Research Center for Allergy and Rheumatology, National Hospital Organization Sagamihara National Hospital, Sagamihara, Kanagawa, Japan. Background: The pathogenesis of aspirin-exacerbated respiratory disease (AERD) is presumed to involve the aspirin/non steroidal anti-inflammatory drug (NSAID)-induced abnormal metabolism of arachidonic acid, resulting in the production of 5-lipoxygenase metabolites, particularly leukotriene C4. Aspirin intolerance occurs around the same time as asthma onset, and a few of the patients with AERD had suffered from pediatric asthma. Although atopy is not associated with the pathogenesis of AERD, some of the patients with AERD have aeroallergen sensitization. There are few studies in which the association between the pathogenesis of AERD and atopy has been clarified. Methods: Ninety AERD patients, whose aspirin sensitivity was determined by the aspirin challenge test, and 100 aspirin-tolerant asthma (ATA) patients, whose age and sex were adjusted, participated in this study. Atopy was defined as a positive reaction in an intradermal test to one or more of 19 common aeroallergens, or a positive reaction above class one in Immuno CAP RAST. We analyzed the relationships between aeroallergen sensitization and clinical settings of AERD patients. Results: The atopic and non atopic AERD groups showed median serum total IgE concentrations of 464 and 130 IU/l (P value ¼ 0.004), respectively. The asthma of atopic patients with AERD was milder than that of non atopic patients with AERD. (P value ¼ 0.05) The Lund-Mackay score of atopic patients with AERD was lower than that of non atopic patients with AERD. (P value ¼ 0.02) Conclusions: Two-thirds of the patients with AERD showed aeroallergen sensitization. The asthma and sinusitis in atopic patients with AERD were significantly milder than those in non atopic patients with AERD. Aeroallergen sensitization might prevent the worsening of asthma in patients with AERD. Methods: Cohort study. Inclusion criteria: Patients with asthma diagnoses, hypersensitivity to aspirin and nasal polyps. Exclusion criteria: Other kind of asthma, COPD. Twelve patients were followed from June 2009 to June 2011. Nasal and bronchial symptoms were assessed every 6 months using the Visual Analogue Scale of severity (VAS) from EPOS guidelines and spirometry from GINA. All were treated with intranasal mometasone furoate 200 mcg at day, montelukast 10 mg at day, salmeterol plus fluticasone 50/100 powder 2 inhalation every 12 hours, fluticasone spray 150 mg every 12 hours, loratadine tablet 10 mg if was necessary, with modifications of doses every 3 months.Patients diagnosed at 6 months with sinusitis and nasal polyposis were administered amoxicillin plus clavulanate 1.5 g daily for 5 weeks. The patients without response at 6 and 18 months were prescribed clarithromycin 400 mg daily for 4 weeks. All patients underwent CT of the sinuses through the Lund-Mackay system, chest CT scan, skin prick test. Evaluated by otolaryngology at the 6, 12, and 18 months. Results: In the 98, 2% had negative skin prick tests. At 6 months, 58.3% had nasal symptoms with VAS ,7. At 33.3% reported bronchial relapses with FEV1 ,80. At year nasal symptoms increased, with WAS. 7 in 66.6%. The bronchial relapse decreased to 16.6%. At year and a half it increased nasal symptoms in 75% of patients, with VAS. 7. At 41.6% had obstruction of 100% and pansinusitis. They needed antibiotic scheme. At 2 years in 83.3% had a VAS.7. At 58.3% had pansinusitis. The bronchial relapse did not increase. We determined the presence of VAS. 7 and pansinusitis (OR ¼ 4). The bronchial relapse did not influence with increasing VAS (OR ¼ 1). Conclusions: Nasal symptoms persistent were secondary to the nasal polyps and pansinusitis with higher levels of VAS. It was determinated a 4-fold risk over pansinusitis with a VAS. 7 (OR ¼ 4). It should be stressed the palliative surgical treatment in earlier stages and desensitization protocols.
Clinics and Laboratory Characteristics of Asthmatic Patients with Aspirin Exacerbated Respiratory Disease (AERD)
Marice Guterrez Roso,MD, Giordana Portela Lima,MD, Jorge Kalil, MD, PhD, Pedro Giavina-Bianchi, MD, PhD, and Rosana Camara Agondi, MD, PhD. Clinical Immunology and Allergy, Sao Paulo University, São Paulo, Brazil. Background: Clinics and laboratory characteristics of asthmatic patients with aspirin exacerbated respiratory disease (AERD): asthma, polyposis and aspirin hypersensitivity. Methods: Asthmatic patients with AERD history were evaluated. They were evaluated about asthma severity, rhinitis severity, history of polypectomy, and atopy. Some complementary exams were performed: total and specific IgE, serum eosinophilia, spirometry and nasal fibroscopy. Results: Forty-seven patients concluded the study. The mean age of the patients was 53.1 years old and eighty-five percent were women. All patients had nasal polyposis and 23 patients (49%) had performed polypectomy. Thirty-nine patients (83%) had moderate/ severe persistent rhinitis and thirty-6 patients (77%) had moderate or severe persistent asthma and all of them were in inhaled corticosteroid treatment. The spirometry was classified as mild obstructive ventilatory disturbed (FEV1 3 60%) in 31 patients (66%). The mean value of total IgE was 427 IU/mL. The mean number of eosinophils was 477 cell/mm 3 . The specific IgE to inhaled allergens was present in 22 patients (47%), who also had family history of atopy. Conclusions: AERD is clinic syndrome related to chronic and severe inflammation of superior and inferior respiratory tracts, and is complicated with chronic rhino sinusitis, recurrent polyposis and asthma. In this study, thirty-six patients (77%) had history of rhino sinusitis and 50% had moderate and severe asthma. Atopy was confirmed in 47% of the patients. Polypectomy was performed as therapeutic treatment in 23 patients (49%). The prevalence of AERD in asthmatic patients is around 40%, and therefore, an early diagnosis is essential.
Association Analysis of Member RAS Oncogene Family Gene Polymorphisms with Aspirin Intolerance in Asthmatic Patients
Myung ok Kim, 1 Choon-Sik Park, 2 and Tae-Hoon Kim 3 . 1 Genome research center for allergy and respiratory disease, buchun, South Korea; 2 Respiratory and allergy, Soonchunhyang University Bucheon Hospital, Bucheon, South Korea; 3 Soonchunhyang University Hospital Genome Research Center for Allergy and Respiratory Disease, Bucheon, South Korea. Background: Member RAS oncogene family (RAB1A) converts small G protein to rab1 protein, a inflammation of blood eosinophils. Thus, functional alterations of the RAB1A gene may contribute to Aspirin exacerbated respiratory disease (AERD). Methods: Asthmatics (n ¼ 1277) were categorized into Aspirin exacerbated respiratory disease (AERD) and aspirin-tolerant asthma (ATA). 8 SNPs were genotyped. Messenger RNA expression of the RAB1A gene by peripheral blood mononuclear cell is measured by Real time PCR and reverse transcriptase polymerase chain reaction (RT-PCR). Human PBMC culture supernatant expression of 11-dehydrothromboxane B2. Protein expression of the RAB1A gene by PBMC is measured by RNAi (Knock down) analysis. Results: The logistic regression analysis showed that the rare allele frequency of 141170 C.G on intron 5 was significantly lower in the AERD group (n ¼ 261) than in the ATA group (n ¼ 1016) (P ¼ 0.002). The linear regression analysis revealed a strong association of 141170 C.G with the aspirin challenge induced-FEV 1 fall (P ¼ 0.00008). RT-PCR and real time PCR revealed an exon-4-deleted variants. The level of full-length RAB1A mRNA did not differ, but the variants was significantly higher in 141170 G homozygotes than in 141170 C homozygotes (P ¼ 0.002). Intron based PCR was was used to amplify transcripts of PBMC pre-mRNA in which intron-5 had been removed (mRNA) while another set of primers was used to amplify intron 5-containing pre-transcripts (premRNA). Knock down analysis of RAB1A Transcripts level in hPBMC. Thromboxane B 2 were increased in the siRNA treated when compared those of scramble and control. After knock down analysis, the levels of thromboxane B 2 were significantly decreased in PBMC culture supernatant. Conclusions: The rare allele of 141170 C.G may play a protective role against aspirin hypersensitivity via a lower catalytic activity of the RAB1A gene attributed to the increase of a non-functioning variants of RAB1A. Background: Changes in nasal nitric oxide (nNO) levels after nasal lysine aspirin (lys-ASA) challenge have not been determined. Methods: Fourteen patients with aspirin induced asthma (AIA) with or without nasal polyps with aspirin were included to the study. Hypersensitivity had to be confirmed by positive result of oral aspirin challenge Ten healthy subjects served as the control group. 12 mg of lys-ASA were applied unilaterally. Nasal symptoms were assessed using visual analogue scale (VAS) and nNO and peak nasal inspiratory flow (PNIF) measurements were performed before and 1, 2, 4 and 24 hours after the challenge. The result of the challenge was considered as positive when at least 20% fall of PNIF as well as 20% increase of total VAS score were observed. Results: Ten patients (71.4%) had clinically positive result of the challenge. We observed significant fall in nNO levels in AIA patients after 1 and 2 hours after the challenge (653. 1 6 420. 2 at baseline versus 490. 3 6 456. 0; P ¼ 0.0029 and 439. 9 6 556. 4 ppb; P ¼ 0.0076; respectively). The decrease in nNO level was more pronounced in patients with clinically positive result of the challenge (510. 1 6 212. 5 at baseline versus 283. 3 6 173. 4; P ¼ 0.005; 159, 6 6 166,1; P ¼ 0.005 and 331. 0 6 312.0 ppb; P ¼ 0.037 after 1, 2 and 3 hours, respectively). In 4 subjects with clinically negative result of the challenge we noticed a trend towards higher nNO concentrations after lys-ASA challenge (1010. 8 6 625. 2 at baseline vs 1341. 3 6 670. 5 ppb after 4 hours). No significant changes in nNO levels after the challenge were observed in healthy controls. Conclusions: NO levels decrease after lys-ASA nasal challenge in subjects with AIA and clinically positive nasal provocation. An unexpected trend towards increase in nNO levels was observed in subjects with AIA and clinically negative provocation Potential usefulness of nNO measurement in aspirin nasal provocation needs further evaluation. 
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